Global Pharma and Biotech Discovery Stage Partnering Terms and Agreements Directory 2012-2018

6/11/2018, 2:41 PM (Source: GlobeNewswire)

Dublin, June 11, 2018 (GLOBE NEWSWIRE) -- The "Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2012- 2018" report has been added to's offering.

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 report.

The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all discovery stage partnering deals announced since 2012 including financial terms where available including over 3,000 links to online deal records of actual discovery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Key benefits

  • In-depth understanding of discovery stage deal trends since 2012
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of discovery stage agreements with numerous real life case studies
  • Insight into the terms included in a discovery stage agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal type
  • Specific therapy target

The report includes deals announced by hundreds of life science companies including big pharma such as:

  • Abbott
  • Abbvie
  • Actavis
  • Amgen
  • Astellas
  • AstraZeneca
  • Baxter
  • Bayer
  • Biogen Idec
  • BMS
  • Celgene
  • Eisai
  • Eli Lilly
  • Gilead
  • GSK
  • J&J
  • Kyowa Hakko
  • Merck
  • Mitsubishi
  • Mylan
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Shire
  • Takeda
  • Teva
  • Valeant

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner at discovery stage?

2.1. Introduction
2.2. The role of discovery stage partnering
2.2.1. In-licensing at discovery stage
2.2.2. Out-licensing at discovery stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into discovery stage partnering deals
2.4.1. Licensors reasons for entering discovery stage deals
2.4.2. Licensees reasons for entering discovery stage deals
2.5. The future of discovery stage partnering deals

Chapter 3 - Discovery stage deal strategies and structure

3.1. Introduction
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical/biotech Discovery and preclinical stage partnering case studies Case study: LEO Pharma - 4SC Case study: Heptares Therapeutics - Cubist Case study: Incyte - Agenus Bio Case study: Janssen Pharmaceutical - Evotec
3.2.2. Partnering later in pharmaceutical/biotech Clinical stage partnering case studies Case study: Servier - GeNeuro Case study: Teva - Xenon Pharmaceuticals Case study: AstraZeneca - Ardelyx Case study: Baxter - Onconova Therapeutics
3.3. Early and later stage partnering - a risk/cost comparison
3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure licensing agreements
3.6.1.a. Case study : Pfizer - Spark Therapeutics
3.6.1.b. Case study : Contrafect - Trellis Bioscience
3.7. Multicomponent discovery stage partnering agreements
3.7.1.a. Example multicomponent early stage clauses
3.7.1.a. Case study: Tracon - Boehringer Ingelheim - Macrogenics
3.7.1.b. Case study: Fibrocell Science - Intrexon

Chapter 4 - Discovery stage partnering payment strategies

4.1. Introduction
4.2. Discovery stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments Conditionality of upfront payments
4.3.3. Loans
4.3.4. Convertible loans
4.3.5. Equity
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments Issues affecting royalty rates Royalties on combination products Case study: Scripps Research Institute-Cyanotech Guaranteed minimum/maximum annual payments Royalty stacking Royalties and supply/purchase contracts
4.3.10. Quids
4.3.11. Option payments

Chapter 5 - Trends in discovery stage deal making

5.1. Introduction
5.2. Discovery stage partnering over the years
5.2.1. Attributes of discovery deals
5.3. Discovery stage partnering by deal type
5.4. Discovery stage partnering by disease type
5.5. Partnering by discovery stage technology type
5.6. Discovery stage partnering by most active company since 2012

Chapter 6 - Payment terms for discovery stage partnering

6.1. Introduction
6.2. Guidelines for discovery stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Discovery stage payment terms - deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Discovery stage headline values
6.4.2. Discovery stage deal upfront payments
6.4.3. Discovery stage deal milestone payments
6.4.4. Discovery stage royalty rates

Chapter 7 - Leading discovery stage deals

7.1. Introduction
7.2. Top discovery stage deals by value

Chapter 8 - Top 50 most active discovery stage dealmakers

8.1. Introduction
8.2. Top 50 most active discovery stage dealmakers

Chapter 9 - Discovery stage partnering contracts directory

9.1. Introduction
9.2. Discovery stage deals with contracts 2012 to 2018

Chapter 10 - Discovery stage deal making by development stage

10.1. Introduction
10.2. Deals by discovery stage


Appendix 1 - Discovery stage dealmaking by companies A-Z
Appendix 2 - Discovery stage dealmaking by industry sector
Appendix 3 - Discovery stage dealmaking by stage of development
Appendix 4 - Discovery stage dealmaking by therapy area
Appendix 5 - Discovery stage dealmaking by technology type

For more information about this report visit

         Laura Wood, Senior Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Biotechnology, Pharmaceuticals, Drug Discovery

Primary Logo

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.